Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 19 August 2019. Michael Carrel.

Executive Summary

AtriCure Inc. has closed a $300m structured deal to acquire SentreHEART Inc., the privately held developer of the Lariat percutaneous left atrial appendage (LAA) closure device. See what AtriCure CEO Michael Carrel said about it here.

"The [deal with SentreHEART] is significant and provides AtriCure with a complementary technology to not only diversify our portfolio, but also an opportunity to further leverage our existing commercial channel in the [electrophysiology] market. By adding the Lariat to their toolkit, physicians can offer a percutaneous epicardial left atrial appendage management solution." – Michael Carrel, CEO, AtriCure Inc.

Click here for a free trial of Medtech Insight

 
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT125515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel